ClinicalTrials.gg
RecruitingNCT02543905PROFILEUpdated Oct 27, 2026

The PROFILE Study: Germline Genetic Profiling: Correlation With Targeted Prostate Cancer Screening and Treatment

An observational study in Prostate Cancer, Prostate Biopsy and Genetic Counselling, sponsored by Institute of Cancer Research, United Kingdom. Recruiting at 1 site in United Kingdom. Open to male participants aged 40 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Institute of Cancer Research, United Kingdom · Observational

How we know

From the registry’s dates

  • Started Mar 2015; still recruiting 11 years 8 months later.
Updated Oct 27, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,600
Ages
40 Years to 69 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Prostatic Neoplasms by Institute of Cancer Research, United Kingdom — 13 open to participants now, 18 under way, 1 of them phase 3. Prostatic Neoplasms · Institute of Cancer Research, United Kingdom.

Planned enrollment
7th of 16
1,600 · median 1,000
Started
2015
with 2 others
Observational
16 of 26
8 open now
Primary completion
2026-12
later than 5 of 17 live
Registered
7th of 26
by date

Among the 26 studies in Prostatic Neoplasms by Institute of Cancer Research, United Kingdom, this one is the 7th largest by planned enrollment of the 16 observational ones that give a count, is one of 3 that started in 2015, is one of 16 observational ones, reaches primary completion later than 5 of the 17 other live ones, and was the 7th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

13 of the 26 studies in Prostatic Neoplasms by Institute of Cancer Research, United Kingdom are open now, in 5 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 40 Years to 69 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Prostatic Neoplasms by Institute of Cancer Research, United Kingdom, or all of them as a file.
02

Study summary

Prostate cancer is now the most common cancer in men in the Western world. In the United Kingdom (UK), there were over 52,000 new cases diagnosed in 2016-2018 and a lifetime risk of 1 in 8. Prostate cancer (PrCa) can run in some families and research studies have identified several genetic changes in Caucasian populations that are thought to increase the risk of developing prostate cancer. Other studies have shown that men from certain ethnic groups also have a higher risk of prostate cancer, and this includes men of black African or black African-Caribbean ancestry. This study aims to look at men with a higher risk of prostate cancer based on their ethnicity, family history and/or genetic predisposition to see whether any of these genetic changes are present in their DNA (genetic material) and whether this could be a helpful screening tool in prostate cancer screening programmes. It is thought that many genetic changes are involved in the development of prostate cancer and research is being carried out worldwide to identify these genetic changes. Some of these changes may cause a very slight increase in prostate cancer risk while others may cause a much larger increase in risk of developing prostate cancer. The investigators will invite (i) men of any ethnicity with a family history of prostate cancer; (ii) men of black African or black African-Caribbean ancestry; and (iii) men of any ethnicity with a known genetic predisposition to having prostate cancer (e.g., being known to have inherited a gene mutation that increases risk of prostate and/or being known to be in the top tenth percentile of the polygenic risk score (high PRS score prior to enrolment) for targeted prostate screening (Prostate Specific Antigen (PSA) testing, MRI and a biopsy of the prostate gland) and genetic profiling. The outcome of these prostate cancer screening investigations will be compared with the genetic profiles of those taking part in the study in order to look for certain genetic changes in the gene code that are thought to increase prostate cancer risk. This research will help us to determine what the role of such genetic profiling is in a prostate cancer screening programme and if it helps identify men at high prostate cancer risk.

Read the detailed description

Purpose and Design

The aim of the PROFILE study is to investigate the role of targeted prostate cancer screening in men at a genetically higher risk to estimate the incidence of PrCa and the sensitivity and specificity of PSA screening in these populations and correlate this with genetic profiles and biological endpoints. Additionally, the study aims to identify biomarkers from biological samples (such as blood and urine) as well as imaging technologies (e.g. MRI and new imaging techniques) as predictive markers of the risk of developing PrCa and to correlate these with genetic risk. This study has been designed using an observational approach to look at the correlation of cancer incidence (on biopsy) with genetic profile. The aim is to evaluate targeted screening for prostate cancer in men at a genetically higher risk to estimate the incidence of prostate cancer and the sensitivity and specificity of PSA screening in these populations and correlate this with genetic profiles (i.e. single nucleotide polymorphism (SNP) profiles) and biological endpoints.

Three cohorts will be recruited:

  1. Men of any ethnicity with family history of prostate cancer.
  2. Men of black African or black African-Caribbean ancestry.
  3. Men of any ethnicity with a genetic predisposition to having prostate cancer (e.g., being known to have inherited a gene mutation that increases risk of prostate cancer (i.e. high-risk gene mutation) and/or being known to have a high polygenic risk score (high PRS score) defined as being in the top tenth percentile prior to enrolment.

Men with no prior screening will be offered biopsy and genetic profiling. This will provide data on genetic profiling and correlation with biopsy irrespective of PSA in men who have not had any previous screening.

A PSA screening algorithm was considered as an alternative to biopsy but there is great controversy over the PSA threshold that should be used as a cut-off. Recent data have shown that a considerable percentage of men with a PSA within normal range have cancer at biopsy. Therefore, it was decided by the Steering Committee that all participants should be offered a biopsy within this study. This will tell us the acceptability of this approach.

Some men may opt not to have biopsy at baseline (i.e. initial stage). These men will be followed up with annual PSA, whereby prostate biopsy would be offered if PSA is above or equal to 1.0ng/ml if the man is aged under 50 years, or where PSA is above or equal to 2.0ng/ml if the man is aged fifty years or over.

Eligibility and Recruitment

Either:

(1) Men of any ethnicity with a positive family history of PrCa defined as:

  • Men with a first degree relative (or second degree if through female line) with histologically or death certificate proven PrCa diagnosed at \<70 years
  • Men with two relatives on the same side of the family with histologically or death certificate proven PrCa where at least one is diagnosed at \<70 years
  • Men with three relatives on the same side of the family with histologically or death certificate proven PrCa diagnosed at any age

Or (2) Men of black African or black African-Caribbean ancestry defined as:

Both parents and all 4 grandparents being either black African or black African-Caribbean.

Or (3) Men of any ethnicity with a genetic predisposition to having prostate cancer e.g., being found to have inherited a gene mutation that increases risk of prostate cancer (e.g. BRCA1, BRCA2, ATM, PALB2, MLH1, MSH2, MSH6, CHEK2 and other DNA repair gene mutations as listed in the study protocol); and/or being known to have a high polygenic risk score (PRS) (defined as being in the top tenth percentile prior to enrolment).

  • Age 40- 69 years
  • WHO performance status 0-2
  • Absence of any psychological, familial, sociological or geographical situation potentially hampering compliance with the study protocol and follow up schedule.

Exclusion criteria

  • Previous cancer with a life expectancy of less than five years.
  • Previous PrCa
  • Negative biopsy within one year before recruitment
  • Comorbidities making prostate biopsy risk unacceptable (anticoagulants or antiplatelet medication including Warfarin, Clopidogrel, Apixaban, Dabigatran or other NOAC (Novel Oral Anti-Coagulant); poorly controlled diabetes, cardiovascular/respiratory disease, immunosuppressive medication or splenectomy).
  • Men with body mass index (BMI) 40 and above.
  • Men with BMI 35 and above plus other co-morbidities.
  • Contraindications to having an MRI (non-MRI compliant pacemakers, aneurysm clips, metallic cardiac valve/stent, Ventriculo-Peritoneal (VP) shunt, cochlear implant, neurotransmitter, metallic foreign bodies in eye(s), other metalwork, claustrophobia)
  • Any significant psychological conditions that may be worsened or exacerbated by participation in the study

Subject Withdrawal

o Subjects may withdraw from the study at any time if they so wish without giving a reason. No further data will be collected about that individual, and any unused samples will be destroyed. Data collected up to that point will be retained for audit purposes.

Cancer cases Men who are found to have prostate cancer at biopsy will be referred to their local urologist for treatment according to local policy. Men will be followed up for 10 years in order to evaluate the different treatment regimens.

Genetic Profiling All men will have genetic profiling to correlate with disease status and men will be given the results of this test. It will be emphasised that these are research results and written information will be provided as a reference guide.

Informed Consent All subjects will be informed of the aims of the study, the possible adverse events, the procedures and possible hazards to which he will be exposed, and the mechanism of treatment allocation if prostate cancer was to be diagnosed. He will be informed as to the strict confidentiality of his patient data, but that his medical records may be reviewed for trial purposes by authorised individuals other than their treating physician.

It will be emphasised that participation in this study is voluntary and that the subject is allowed to refuse further participation in the protocol whenever he wants. This will not prejudice the subject's subsequent care. Documented informed consent will be obtained, according to the principals of good clinical practice (GCP), for all subjects included in the study before they are registered onto the study.

Risks, burdens, benefits There is a risk of complications from having a prostate biopsy, and these complications are detailed in the patient information sheet, together with likelihood of incidence. Complications are rare and standard procedures will be followed at all sites to minimise their occurrence. The benefit of taking part may be that prostate cancer may be diagnosed in men previously unaware that they had the disease. While there is the potential for overdiagnosis of indolent disease, there is also the potential for detecting and treating clinically significant disease.

Provision of results from the genetic profiling One further consideration is the occurrence of anxiety as a result of taking part in the study, particularly in receiving research genetic test results. There is considerable uncertainty about how genetic profile relates to predicted risk of prostate cancer. For this reason individualised written information will be provided to each participant putting the research results in the context of the current population risks. It will be stressed that these are research results only and that the investigators do not fully understand the meaning of the results.

A psychosocial study is being run concurrently and will explore these issues in more depth and the participant's experience of receiving these results will be an important component of the evaluation of this study.

Confidentiality All information which is collected will be accessible only to the immediate study team. Any data that is shared will be de-identified and any published data will be anonymised so that no participant is recognisable from the results.

Medical records and the data collected for the study may be looked at by authorised persons from the Institute of Cancer Research, by regulatory authorities and by authorised people to check that the study is being carried out correctly. All will have a duty of confidentiality to participants.

End of Study Follow-up After the participant has completed the study they will be advised about any ongoing screening or follow-up that is required. This will be organised through the participants general practitioner (GP).

Use of samples in future research The informed consent process will explain that samples are donated as a "gift". If any of the samples collected are to be considered for use in future research projects this would have to be approved by the Ethics Committee first.

03

Conditions studied

  • Prostate Cancer
  • Prostate Biopsy
  • Genetic Counselling
  • Genetic Markers

Browse trials for

04

Who can participate

Ages eligible
40 Years to 69 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

350 men in each cohort*

*The family history cohort will overrecruit to a total of 800, until 350 participants undergo MRI \& biopsy; both the Black and high-risk gene cohorts will overrecruit to a total of 400 participants each, to replace any participants who withdrew and/or any protocol non-compliant cases (e.g. those who underwent MRI but did not complete the biopsy).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Either:

  1. Men of any ethnicity with a positive family history of PrCa defined as:

    • Men with a first degree relative (or second degree if through female line) with histologically or death certificate proven PrCa diagnosed at \<70 years
    • Men with two relatives on the same side of the family with histologically or death certificate proven PrCa where at least one is diagnosed at \<70 years
    • Men with three relatives on the same side of the family with histologically or death certificate proven PrCa diagnosed at any age

    Or

  2. Men of black African or black African-Caribbean ancestry defined as:

    Both parents and all 4 grandparents being of either black African or black African-Caribbean ancestry.

    Or

  3. Men of any ethnicity with a genetic predisposition to having prostate cancer e.g., being known to have inherited a gene mutation that increases risk of prostate cancer (e.g. BRCA1, BRCA2, ATM, PALB2, MLH1, MSH2, MSH6, CHEK2 and other DNA repair gene mutations as listed in the study protocol); and/or being known to have a high polygenic risk score (PRS) (defined as being in the top tenth percentile prior to enrolment).

    • Age 40- 69 years
    • 0-2
    • Absence of any psychological, familial, sociological or geographical situation potentially hampering compliance with the study protocol and follow up schedule.

Exclusion criteria

Exclusion Criteria:

  • Previous cancer with a of less than five years.
  • Previous PrCa
  • Negative within one year before recruitment
  • Co-morbidities making prostate biopsy risk unacceptable (anticoagulants or antiplatelet medication including Warfarin, Clopidogrel, Apixaban, Dabigatran or other NOAC (Novel Oral Anti-Coagulant); poorly controlled diabetes, cardiovascular/respiratory disease, medication or splenectomy)
  • Men with (BMI) 40 and above.
  • Men with BMI 35 and above plus other co-morbidities.
  • to having an MRI (non-MRI compliant pacemakers, aneurysm clips, metallic cardiac valve/stent, Ventriculo-Peritoneal (VP) shunt, cochlear implant, neurotransmitter, metallic foreign bodies in eye(s), other metalwork, claustrophobia)
  • Any significant psychological conditions that may be worsened or exacerbated by participation in the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,600 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Family History Cohort

    Men of any ethnicity with a family history of prostate cancer defined as: * Men with a first degree relative (or second degree if through female line) with histologically or death certificate proven PrCa diagnosed at \<70 years * Men with two relatives on the same side of the family with histologically or death certificate proven PrCa where at least one is diagnosed at \<70 years * Men with three relatives on the same side of the family with histologically or death certificate proven PrCa diagnosed at any age

    Procedure: Prostate MRI and Biopsy

  • Black African / Black African-Caribbean Cohort

    Men of black African or black African-Caribbean ancestry defined as: Both parents and all 4 grandparents being of black African or black African-Caribbean ancestry.

    Procedure: Prostate MRI and Biopsy

  • High-risk gene mutation cohort

    Men of any ethnicity with a genetic predisposition to having prostate cancer e.g., being known to have inherited a gene mutation that increases risk of prostate cancer (gene mutation including BRCA1, BRCA2, ATM, PALB2, MLH1, MSH2, MSH6, CHEK2 and other DNA repair gene mutations as listed in the study protocol); and/or being known to have a high polygenic risk score (PRS) (defined as being in the top tenth percentile prior to enrolment).

    Procedure: Prostate MRI and Biopsy

Interventions

  • ProcedureProstate MRI and Biopsy

    All men will be offered a MRI and prostate biopsy and they can either opt to undergo these procedures at baseline irrespective of PSA level at baseline or they can undergo PSA-only screening until clinically indicated based on an age-defined PSA threshold, at which point, they will undergo prostate MRI and biopsy once their PSA reaches the threshold.

06

What researchers measure

Primary outcomes

  1. The association of specific genetic profiles and biomarkers to predict outcome of prostate screening in men at higher genetic risk

    To investigate the role of targeted prostate cancer screening in men at higher genetic risk (i.e. family history, ethnicity, gene mutation status), its association with specific genetic profiles and biomarkers as predictive tools of the risk of developing prostate cancer and to correlate these with genetic risk.

    Time frame: 5 years

Secondary outcomes

  1. The incidence and aggressiveness of prostate cancer in men at higher genetic risk.

    To determine the incidence and aggressiveness of prostate cancer in these men at a higher genetic risk.

    Time frame: 5 years

  2. The association of Diffusion Weighted MRI (DW-MRI) findings with prostate biopsy results.

    To determine whether imaging techniques such MRI can be used to identify prostate cancer when compared to prostate biopsy results.

    Time frame: 5 years

  3. The incidence of abnormal imaging (using 3D ultrasound combined with shear wave elastography) and correlation with biopsy outcome and to correlate standard 12 core prostate biopsies with targeted biopsies based on abnormalities identified at DWMRI.

    To determine the incidence of abnormal imaging at MRI in correlation with biopsy outcome.

    Time frame: 5 years

  4. The association of biological sample biomarker profiles with prostate biopsy result.

    To identify biomarkers from biological samples and determine their association with prostate biopsy result.

    Time frame: 5 years

  5. The association of quantitative imaging biomarkers with prostate biopsy result

    To identify imaging biomarkers and determine their association with prostate biopsy result.

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
  • Institute of Cancer Research and Royal Marsden Hospital
    Sutton, Surrey SM2 5PT, United Kingdom
    Recruiting
    • Rosalind A Eeles, FRCP FRFR · Contactrosalind.eeles@icr.ac.uk · 02086613642
    • Rosalind A Eeles, FRCP FRCR · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Anonymised data can be applied for via the Data Access Committee

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2015 (actual). Primary completion is estimated for Dec 2026, 141 months after the start.

Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 141 months is above that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Dec 2030, on Oct 27, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2015
First posted
Sep 7, 2015
StartActual
Mar 9, 2015
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2030was Dec 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Dec 31, 2026→Dec 31, 2030
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Study completion Dec 31, 2026→Dec 31, 2030
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02543905
Responsible party
Sponsor
First posted
Sep 7, 2015
Start date
Mar 9, 2015
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Oct 27, 2026

Study contacts

Elizabeth K Bancroft, PhD
Contact
elizabeth.bancroft@icr.ac.uk
44 207 808 2136
Eva McGrowder, PhD
Contact
eva.mcgrowder@icr.ac.uk
44 208 722 4483
Rosalind A Eeles
principal investigator · Institute of Cancer Research, United Kingdom

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion